Medaysis
Enable Innovation

DATA SHEET

Rabbit Anti-BRAF V600E [MD58R]: RM0244

Intended Use: For Research Use Only

Description: Serine/threonine-protein kinase B-raf (BRAF) is a member of the Raf family. BRAF mutations are frequent in benign and malignant human tumors. BRAF V600E mutation accounts for the vast majority of BRAF alterations and the mutation induces a conformational change of the activation segment leading to a constitutive kinase activity of BRAF and consecutive phosphorylation of downstream targets. BRAF V600E mutation have been detected in melanoma, papillary thyroid carcinoma, pleomorphic xanthoastrocytomas, Langerhans cell histiocytosis, borderline ovarian cancer, ganglioglioma, colorectal carcinoma, and pilocytic astrocytoma.

Specifications:

Clone:	MD58R
Source:	Rabbit
Isotype:	IgG
Reactivity:	Human
Immunogen:	Peptide corresponding to BRAF V600E mutant
Localization:	Cytoplasm
Formulation:	Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC, ELISA, ICC, WB

Package:

Description	Catalog No.	Size
BRAF V600E Concentrated	RM0244	1 ml

IHC Procedure*:

Positive Control Tissue:	Colon carcinoma with BRAF V600E mutation
Concentrated Dilution:	10-100
Pretreatment:	Tris EDTA pH9.0, 15 minutes Pressure Cooker or 30-60 minutes water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human thyroid carcinoma stained with anti-BRAF V600E using DAB

References:

1. Clinical utility of immunohistochemistry using the novel anti-BRAF V600E antibody (clone RM8) for detection of the BRAF V600E mutant protein in papillary thyroid cancers. Krishnamurthy A et al. Int J Mol Immuno Oncol. 10.18203/issn. 2456-3994, 2018.
2. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas. Gouravan S et al. Int J Mol Sci. 2018.
3. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Yang H et al. Oncogene. 10.1038/onc.2016.526, 2017.

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 510-509-3153 www.medaysis.com